Shocking Retatrutide Results Show Double Ozempic Weight Loss

Image Source: Reuters

Retatrutide, Eli Lilly’s experimental next-generation weight loss drug, produced more than twice the average weight loss of the highest dose of Ozempic in a new phase 3 clinical trial, according to results shared Wednesday and reported by ABC News.

The 80-week study included more than 1,000 adults with type 2 diabetes. Participants receiving the 9-milligram dose of retatrutide lost an average of 44.3 pounds, while those taking the 12-milligram dose lost an average of 47.4 pounds. By comparison, participants receiving Ozempic’s highest 2-milligram dose lost an average of 20.9 pounds.

Retatrutide delivers powerful weight loss results

The findings highlight the potential of retatrutide, which Eli Lilly describes as a new type of treatment in the rapidly expanding obesity and diabetes drug market. The medication is designed as a once-weekly injection and works differently from several currently available treatments.

Retatrutide imitates the effects of three hormones involved in appetite, blood sugar regulation and energy use: GLP-1, GIP and glucagon. Ozempic and Wegovy, made by Novo Nordisk, target GLP-1. Eli Lilly’s Mounjaro and Zepbound target both GLP-1 and GIP.

Glucagon may offer an additional effect. The hormone is associated with promoting fat burning, including when the body is at rest. Researchers believe that combining the three pathways could help explain the drug’s notable weight loss results.

Clinical trial shows broader health benefits

Weight reduction was not the only encouraging result. The trial also found that retatrutide improved several health measures connected to type 2 diabetes and cardiovascular risk.

• Participants experienced greater average weight loss at both tested doses.
• The drug reduced A1C, a key measure of blood sugar control.
• A1C fell by 2.2% among participants taking retatrutide, compared with 1.8% for those taking Ozempic.
• Researchers also observed improvements in cholesterol and blood pressure.

For people living with type 2 diabetes, these changes could be clinically important. Better blood sugar control, healthier cholesterol levels and lower blood pressure may reduce the risk of serious complications over time. However, the trial results do not mean the medication is currently available as an approved treatment.

FDA approval is still several steps away

Eli Lilly said it plans to submit retatrutide for approval by the U.S. Food and Drug Administration in early 2027. The FDA will then review the clinical evidence, safety information and manufacturing details before deciding whether the medicine can be sold in the United States.

Retatrutide is not FDA approved at this time. That means patients cannot legally obtain it through a standard prescription, and its safety and effectiveness are still being evaluated through clinical research.

Novo Nordisk is also developing an experimental weight loss drug called CagriSema, which the company expects could receive FDA approval by the end of the year. The competition reflects the growing demand for treatments that can address obesity, diabetes and related health risks.

Warning issued about online versions

Health officials have warned consumers not to purchase or use versions of retatrutide sold online. According to the FDA, products marketed through black-market channels may be counterfeit, contaminated, incorrectly dosed or made with unknown ingredients.

Unapproved injections can pose serious risks, especially when consumers do not know how the product was manufactured or stored. Anyone considering a prescription weight loss medication should speak with a qualified health care provider rather than relying on online sellers or unverified products.

Ozempic and Mounjaro are FDA approved to treat type 2 diabetes. Wegovy and Zepbound are approved for certain people with overweight or obesity. Approval status, eligibility and dosage differ from one medication to another, so treatment decisions should be made with medical supervision.

What the results could mean for weight loss treatment

The new results could strengthen Eli Lilly’s position in the race to develop more effective obesity medicines. Retatrutide’s three-hormone approach may eventually offer another option for people who do not achieve sufficient results with existing GLP-1 or dual-action medications.

Still, researchers and regulators will need to examine the full safety profile before the drug can reach patients. Long-term effects, side effects, tolerability and outcomes beyond the 80-week trial period will all be important parts of the FDA review.

For now, the results are promising but preliminary from a consumer perspective. Retatrutide appears to have produced substantial weight loss and improvements in important metabolic measures, but it remains an investigational medicine rather than an approved treatment.

Frequently asked questions

What is retatrutide?

Retatrutide is an experimental once-weekly injection developed by Eli Lilly. It targets three hormone pathways: GLP-1, GIP and glucagon.

How much weight did participants lose?

In the 80-week trial, participants lost an average of 44.3 pounds with the 9-milligram dose and 47.4 pounds with the 12-milligram dose.

Is retatrutide FDA approved?

No. Eli Lilly plans to submit the drug for FDA approval in early 2027, but it is not currently approved or legally available as a standard prescription.

Is retatrutide available online?

Consumers should not buy or use online versions. The FDA has warned that products sold through black-market sources may be unsafe, contaminated or inaccurately labeled.